Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: p53-HDM2 inhibitors - Ascenta Therapeutics

Drug Profile

Research programme: p53-HDM2 inhibitors - Ascenta Therapeutics

Alternative Names: MI-147; MI-219; MI-43; MI-519-64; MI-63

Latest Information Update: 16 Jul 2016

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Michigan
  • Developer Ascenta Therapeutics
  • Class Small molecules
  • Mechanism of Action Apoptosis stimulants; Proto-oncogene protein c-mdm2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in USA (PO)
  • 04 Jun 2010 Drug candidates from the research programme licensed to sanofi-aventis worldwide ,
  • 11 Dec 2007 Pharmacodynamics data from a preclinical study in cancer presented at the 49th Annual Meeting and Exposition of the American Society of Hematology (ASH-2007)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top